Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial

Journal of Infectious Diseases

Volumn 195, Issue 12, 2007, Pages 1818-1827

  Tam, V H ^a,d   Louie, A ^a   Fritsche, T R ^b   Deziel, M ^a   Liu, W ^a   Brown, D L ^a   Deshpande, L ^b   Leary, R ^c,e   Jones, R N ^b   Drusano, G L ^a,f  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b JMI LABORATORIES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF HOUSTON   (United States)

^e PHARSIGHT CORPORATION   (United States)

^f Drdway Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GARENOXACIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EXPOSURE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, THEORETICAL; POLYMERASE CHAIN REACTION; PROTEIN BINDING; REPRODUCIBILITY OF RESULTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 34249870835     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/518003     Document Type: Article

References (14)

1. Jumbe N, Louie A, Leary R. et al. Application of a mathematical model to prevent in-vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003; 112:275-85.
2. Tam VH, Louie A, Deziel MR, Liu W, Leary R, Drusano GL. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis 2005; 192:420-8.
3. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS publication M7-A4. Wayne, PA: NCCLS, 1997.
4. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. CLSI publication M7-A7. Wayne, PA: CLSI, 2006.
5. Horii T, Suzuki Y, Monji A, et al. Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus: effects of the mutations on fluoroquinolone MICs. Diagn Microbiol Infect Dis 2003; 46:139-45.
6. Craig WA, Suh B. Protein binding and the antimicrobial effects: methods for the determination of protein binding. In: Lorian V, ed. Antibiotics in laboratory medicine. 2nd ed. Baltimore, MD: Williams & Wilkins, 1986:477-514.
7. Bristol-Myers Squibb Pharmaceutical Research Institute. Investigator brochure (BMS-284756). Wallingford, CT: Bristol-Myers Squibb. 1999.
8. Leary R, Jelliffe R, Schumitzky A, Van Guilder M. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. In: Proceedings of the 14th IEEE Symposium on Computer-Based Medical Systems. Bethesda, MD: IEEE Computer Society, 2001; 389-94.
9. D'Argenio DZ, Schumitzky A. ADAPT 11: a program for simulation, identification, and optimal experimental design (user manual). Los Angeles, CA: Biomedical Simulations Resource, University of Southern California, 1997. Available at: http://bmsr.usc.edu/. Accessed December 2006.
10. Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45:433-8.
11. Chung P, McNamara PJ, Campion JJ, Evans ME. Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50:2957-65.
12. Campion JJ, Chung P, McNamara PJ, Titlow WB, Evans ME. Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:2189-99.
13. MacGowan AP, Bowker KE, Wootton M, Holt HA. Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection. Antimicrob Agents Chemother 1999; 43:1560-4.
14. MacGowan AP, Rogers CA, Holt HA, Bowker KE. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2003; 47:1088-95.